Results 261 to 270 of about 145,684 (315)
Some of the next articles are maybe not open access.

When IBD is not IBD

Scandinavian Journal of Gastroenterology, 2018
Entamoeba histolytica colitis can mimic Crohn's disease. However, a fulminant infection can be life-threatening, especially after exposure to systemic steroids. We present a case of the patient who was initially diagnosed with ileocolonic Crohn's disease, but developed a hepatic E histolytica abscess while undergoing anti-TNF therapy. After revision of
Bram Verstockt   +3 more
openaire   +2 more sources

The IBD and PSC Phenotypes of PSC-IBD

Current Gastroenterology Reports, 2018
To review the characteristics of IBD and PSC that occur in association, as well as their reciprocal influences on disease evolution, in adult and pediatric populations.IBD co-existing with PSC is genetically and clinically distinct from IBD alone. It is frequently characterized by pancolitis, rectal sparing, and possibly backwash ileitis, as well as a ...
Amanda, Ricciuto   +2 more
openaire   +2 more sources

IBD and spondyloarthritis: joint management

Nature Reviews Gastroenterology & Hepatology, 2015
Spondyloarthritis (SpA) is the most common extraintestinal manifestation of IBD. SpA symptoms are not always recognized in patients with IBD. Subsequently, patients with symptoms of SpA can be underdiagnosed, with effective treatment delayed. Cooperation between gastroenterologists and rheumatologists is necessary and, ideally, an integrated management
GIONCHETTI, PAOLO, RIZZELLO, FERNANDO
openaire   +3 more sources

Infections and IBD

Nature Clinical Practice Gastroenterology & Hepatology, 2008
An interaction between infection and IBD was identified soon after Crohn's disease and ulcerative colitis were first described. Since then it has become apparent that infectious agents are involved with both the etiopathogenesis and clinical course of IBD on several levels.
Peter M, Irving, Peter R, Gibson
openaire   +2 more sources

Probiotics and Antibiotics in IBD

Digestive Diseases, 2014
The involvement of the gut microbiota in the pathogenesis of IBD is supported by many findings and is thus now commonly acknowledged. The imbalance in the composition of the microbiota (dysbiosis) observed in IBD patients is one of the strongest arguments and provides the rationale for a therapeutic manipulation of the gut microbiota.
Jørgensen, Nils B   +10 more
openaire   +4 more sources

Probiotics and IBD.

Acta gastro-enterologica Belgica, 2013
The pathophysiology of inflammatory bowel disease is still incompletely understood. While the development of the immune system and the establishment of the microflora take place during infancy young patients often have a more severe and extensive disease.
De Greef, E.   +4 more
openaire   +2 more sources

Fishing for missing heritability in IBD

Nature Reviews Gastroenterology & Hepatology, 2015
A genetic predisposition to IBD is widely accepted; however IBD heritability is dependent on more than the simple additive risk of genetic variants. In a new study using zebrafish, convincing evidence is presented that alterations in the epigenetic regulation of TNF might contribute to the "missing heritability" of IBD.
openaire   +2 more sources

The gut-adherent microbiota of PSC–IBD is distinct to that of IBD

Gut, 2016
Primary sclerosing cholangitis–IBD (PSC–IBD) is an inflammatory autoimmune hepato–biliary–enteric disease in which it is predicted that gut microbiota have potential pathophysiological effects, relevant to disease initiation and outcome. The recent article by Kummen et al 1 who reported that the gut microbiota in PSC is distinct compared with those ...
Quraishi, Mohammed Nabil   +10 more
openaire   +3 more sources

State of the Art: Ibd Therapy and Clinical Trials in Ibd

Inflammatory Bowel Diseases, 2005
Inflammatory bowel diseases (IBD) encompass Crohn's disease and ulcerative colitis, which are diseases characterized by chronic intestinal inflammation. IBD is believed to result from predisposing genetic and environmental factors (specific antigens and pathogen-associated molecular patterns) acting on the immunoregulatory system and causing ...
Kim L, Isaacs   +4 more
openaire   +2 more sources

IBD in 2013: enriching the therapeutic armamentarium for IBD.

Nature reviews. Gastroenterology & hepatology, 2014
In 2013, several new IBD drugs, including golimumab and vedolizumab, have been approved or completed successful programmes, showing efficacy in both Crohn’s disease and ulcerative colitis. In addition, classic IBD drugs have been formulated for colonic delivery, such as budesonide MMX®, which was recently approved for mild-to-moderate ulcerative ...
Danese S, Peyrin-Biroulet L
openaire   +2 more sources

Home - About - Disclaimer - Privacy